19 Jul 2021 8:08 am
It has already been done many times, you ****, moonbatty idiot!!! Big parma in cahoots with CDC, FDA and NIH do not want Ivermectin as the go to preventative and cure for the communist chinese wuhan virus because big pharma cannot profit BILLIONS from its use. THAT IS A FACT!!!IkeBana » 18 Jul 2021, 5:20 pm » wrote: ↑ The only information provided here referred to some in vitro testing done in the UK? I may be wrong about the location. Yours is the first mention of any in vivo testing that I have seen. Gotta link? But so what? Somewhere somebody did a trial with monkeys, rats, and/or innocent furry little bunnies? So what?
Show me the double blind testing on human beings and maybe we can talk about it.
Epub 2020 Dec 2.
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
- PMID: 33278625
- PMCID: PMC7709596
Abstract
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.Keywords: Bangladesh; COVID-19; Doxycycline; Ivermectin; SARS-CoV-2.Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.Conflict of interest statementThe authors declare that there are no known competing financial interests or personal relationships that could have appeared to influence the work described in this paper.Figures
Figure 1 Cumulative viral recovery estimates in…Similar articles
- Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C, Chaparro Campias E, Achinelli F, Guglielmone HA, Ojeda J, Medina F, Farizano Salazar D, Andino G, Ruiz Diaz NE, Kawerin P, Meza E, Dellamea S, Aquino A, Flores V, Martemucci CN, Vernengo MM, Martinez SM, Segovia JE, Aguirre MG.Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1.PMID: 33234158 Free PMC article. Clinical Trial. - Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.PMID: 33115543 Free PMC article. - The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C, Ruiz-Castillo P, Richardson MA, Moncunill G, Casellas A, Carmona-Torre F, Giráldez M, Mota JS, Yuste JR, Azanza JR, Fernández M, Reina G, Dobaño C, Brew J, Sadaba B, Hammann F, Rabinovich R.Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.PMID: 32513289 Free PMC article. - Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, de Oliveira RN, Pena L.J Control Release. 2021 Jan 10;329:758-761. doi: 10.1016/j.jconrel.2020.10.009. Epub 2020 Oct 7.PMID: 33038449 Free PMC article. Review. - The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans DA, Wagstaff KM.Biochem Biophys Res Commun. 2021 Jan 29;538:163-172. doi: 10.1016/j.bbrc.2020.10.042. Epub 2020 Oct 21.PMID: 33341233 Free PMC article. Review.
- COVID-19: A game of drugs, vaccines, hope and… death!
Samantaray A, Johnson E, Kumar N, Mehdiratta L.Indian J Anaesth. 2021 Jun;65(6):434-438. doi: 10.4103/ija.ija_508_21. Epub 2021 Jun 22.PMID: 34248185 Free PMC article. No abstract available. - Key summary of German national treatment guidance for hospitalized COVID-19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021).
Malin JJ, Spinner CD, Janssens U, Welte T, Weber-Carstens S, Schälte G, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Rabe KF, Hoffmann F, Böttiger BW, Weinmann-Menke J, Kersten A, Berlit P, Krawczyk M, Nehls W, Fichtner F, Laudi S, Stegemann M, Skoetz N, Nothacker M, Marx G, Karagiannidis C, Kluge S.Infection. 2021 Jul 6:1-14. doi: 10.1007/s15010-021-01645-2. Online ahead of print.PMID: 34228347 Free PMC article. - Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.
Alam S, Kamal TB, Sarker MMR, Zhou JR, Rahman SMA, Mohamed IN.Front Pharmacol. 2021 Jun 14;12:659577. doi: 10.3389/fphar.2021.659577. eCollection 2021.PMID: 34220503 Free PMC article. Review. - Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C, Chaparro Campias E, Medina MF, Achinelli F, Guglielmone HA, Ojeda J, Farizano Salazar D, Andino G, Kawerin P, Dellamea S, Aquino AC, Flores V, Martemucci CN, Martinez SM, Segovia JE, Reynoso PI, Sosa NC, Robledo ME, Guarrochena JM, Vernengo MM, Ruiz Diaz N, Meza E, Aguirre MG.BMC Infect Dis. 2021 Jul 2;21(1):635. doi: 10.1186/s12879-021-06348-5.PMID: 34215210 Free PMC article. Clinical Trial. - Use of Antimicrobials among Suspected COVID-19 Patients at Selected Hospitals, Bangladesh: Findings from the First Wave of COVID-19 Pandemic.
Mah-E-Muneer S, Hassan MZ, Biswas MAAJ, Rahman F, Akhtar Z, Das P, Islam MA, Chowdhury F.Antibiotics (Basel). 2021 Jun 18;10(6):738. doi: 10.3390/antibiotics10060738.PMID: 34207020 Free PMC article.